
IndraLab
Statements
reach
"In the 4T1 mammary carcinoma model, we have previously shown that B/I selectively activates CD62L- or sensitized T cells and that the anti-tumor activity resides in the CD62L- fraction of lymphocytes obtained from donor lymph nodes; only the CD62L- subset proliferates after B/I activation and has anti-tumor activity [XREF_BIBR]."